Review of Selected 2-Phenylethylamine Derivatives and Opioids, Systematic Review of Their Effects on Psychomotor Abilities and Driving Performance: Psychopharmacology in the Context of Road Safety
Authors:
- Kacper ŻełabowskiKŻKacper Żełabowski
- Kamil BiedkaKBKamil Biedka
- Wojciech PichowiczWPWojciech Pichowicz
- Maria SterkowiczMSMaria Sterkowicz
- Izabela RadzkaIRIzabela Radzka
- Ignacy IlskiIIIgnacy Ilski
- Michał WesołowskiMWMichał Wesołowski
- Kacper WojtysiakKWKacper Wojtysiak
- Wiktor PetrovWPWiktor Petrov
- Dawid ŚlebiodaDŚDawid Ślebioda
- Maciej RzącaMRMaciej Rząca
- Agnieszka Chłopaś-KonowałekACAgnieszka Chłopaś-Konowałek
Open Access
- 16 October 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (10) , 1555
Abstract
Background: Driving is a coordinated psychomotor activity that involves reaction time, attention, and decision-making. Psychoactive substances such as 2-phenylethylamine (PEA) derivatives and opioids may affect these functions and contribute to traffic safety. This systematic review revealed the effects of the selected PEA derivatives and opioids on psychomotor performance among drivers and potential road safety outcomes. Methods: The review followed PRISMA 2020 standards. Using the PICO method, we conducted a systematic search in Embase, PubMed, and Web of Science (2000–2025). Included studies involved adult participants and quantified the effect of PEA derivatives or opioids on driving-related psychomotor function. Thirty-one articles, such as randomized controlled trials, crossover studies, observational studies, and simulator-based studies, were examined. Risk of bias was evaluated using the RoB2 tool. Results: Evidence indicates therapeutic amphetamine and methylphenidate doses can enhance psychomotor function and safety in patients with ADHD. Recreational or high-dose use of methamphetamine and MDMA is associated with impaired coordination, variable speed, and increased impulsivity. Opioid effects are tolerance- and dose-dependent. Small therapeutic doses of fentanyl in chronically treated patients do not notably impair driving. On the other hand, methadone and tramadol commonly cause somnolence, retardation of reaction, and increased accident risk. Conclusions: The impact of opioids and PEA derivatives on psychomotor function is multifactorial, depending on dose, time, route of administration, and patient status. These substances can either improve or impair driving safety. The findings confirm the need for individual-specific pharmacotherapy treatment. They also highlight the importance of further studies to formulate evidence-based clinical and legislative guidelines.Keywords
This publication has 120 references indexed in Scilit:
- Prevalence of Impairing Substance Use in Injured DriversJAMA Network Open, 2025
- Current Pharmacological Treatments for ADHD2022
- Urinary phenylethylamine metabolites as potential markers for sports drug testing purposesBiomedical Chromatography, 2021
- MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐AnalysisThe Journal of Clinical Pharmacology, 2021
- Methadone Destabilizes Cardiac Repolarization During SleepClinical Pharmacology & Therapeutics, 2021
- The effect of d-methamphetamine on simulated driving performanceHuman Psychopharmacology: Clinical and Experimental, 2012
- Functional brain mapping of actual car-driving using [18F]FDG-PETAnnals of Nuclear Medicine, 2006
- The effects of dexamphetamine on simulated driving performancePsychopharmacology, 2004
- Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safetyPsychopharmacology, 2004
- General anesthesia does not impair simulator driving skills in volunteers in the immediate recovery period — a pilot studyCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2003